Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00809185 · ClinicalTrials.gov registry record · Phase 2
RAD001(Everolimus) in Treating Patients With Myelodysplastic Syndromes
A Phase 2 study, sponsored by Case Comprehensive Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00809185 is a Phase 2 study that was terminated before completion, run by Case Comprehensive Cancer Center. The registered enrollment target is 7 participants.
The verdict
NCT00809185, a Phase 2 study, was terminated before completion, sponsored by Case Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
RATIONALE: RAD001(Everolimus) may stop the growth of cancer cells by blocking some of the enzymes needed for their growth and by blocking blood flow to the cancer. PURPOSE: This phase II trial is studying how well RAD001(everolimus) works in treating patients with myelodysplastic syndromes.
Interventions
- OTHER laboratory biomarker analysis
- DRUG everolimus
- PROCEDURE Bone marrow aspirate/biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2005-11 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00809185
The ClinicalTrials.gov registry entry for NCT00809185 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00809185 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00809185 about?
NCT00809185 is a clinical study titled "RAD001(Everolimus) in Treating Patients With Myelodysplastic Syndromes". RATIONALE: RAD001(Everolimus) may stop the growth of cancer cells by blocking some of the enzymes needed for their growth and by blocking blood flow to the cancer. PURPOSE: This phase II trial is studying how well RAD001(everolimus) works in treating patients with myelodysplastic syndromes.
What is the current status of trial NCT00809185?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2005-11. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00809185?
The interventions under investigation include: laboratory biomarker analysis (OTHER), everolimus (DRUG), Bone marrow aspirate/biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT00809185?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.